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Conotruncal and related heart defects (CTRD) are common, complex malformations. Although there are few established risk
factors, there is evidence that genetic variation in the folate metabolic pathway inﬂuences CTRD risk. This study was undertaken
to assess the association between inherited (i.e., case) and maternal gene-gene interactions in this pathway and the risk of CTRD.
Case-parent triads (n = 727), ascertained from the Children’s Hospital of Philadelphia, were genotyped for ten functional variants
of nine folate metabolic genes. Analyses of inherited genotypes were consistent with the previously reported association between
MTHFR A1298C and CTRD (adjusted P = .02), but provided no evidence that CTRD was associated with inherited gene-gene
interactions. Analyses of the maternal genotypes provided evidence of a MTHFR C677T/CBS 844ins68 interaction and CTRD
risk (unadjusted P = .02). This association is consistent with the eﬀects of this genotype combination on folate-homocysteine
biochemistry but remains to be conﬁrmed in independent study populations.
1.Introduction
Congenital heart defects (CHDs) are a heterogeneous group
of malformations with a birth prevalence that approaches
1per 100 [1]. In addition to being the most common type
of structural birth defect, CHDs have a major impact on
pediatric morbidity and mortality [2]. Although CHDs can
occur in association with several known teratogenic (e.g.,
anticonvulsants and maternal pregestational diabetes) and
genetic (e.g., 22q11 deletion and Alagille) syndromes [3, 4],
most CHDs (approximately 80%) appear to be nonsyn-
dromic [5] and are thought to have a complex etiology
involving interactions between several factors. However,
relatively little is known about the speciﬁc risk factors for
non-syndromic CHDs, and there are currently no strategies
forreducing the public health impact of these conditions [3].
The identiﬁcation of CHD risk factors is complicated
by several issues. For example, since CHDs develop during
gestation, studies aimed at identifying genetic risk factors
should consider the eﬀects of both the maternal genotype
and the inherited genotype (i.e., the genotype inherited by
the case) [6]. Further, as CHDs are complex conditions, the
identiﬁcation of risk factors may require the simultaneous
assessment of multiple factors (e.g., gene-gene interactions).
In addition, since CHDs are a heterogeneous group of
conditions, analyses may need to be restricted to subgroups
of phenotypes that are likely to be relatively homogeneous
[7].
The present study was undertaken to extend our studies
of the relationship between conotruncal and related heart
defects (CTRD), which are thought to comprise a relatively
homogenous subset of CHDs, and variation within genes in
the folate metabolic pathway. This pathway was selected for
analysis given evidence that, similar to neural tube defects,
the risk of CHDs in general, and of CTRD in particular, is
inﬂuenced by maternal folate status (reviewed in [3]), as well
as variation within genes that comprise the folate metabolic
pathway [8–11]. As there are few other clues regarding
the causes of non-syndromic CTRD, additional studies of
the association between genetic variation within the folate2 Journal of Biomedicine and Biotechnology
metabolic pathway and the risk of CTRD are strongly war-
ranted. Moreover, conﬁrmation of an association between
CTRD and the folate metabolic pathway would suggest
potential, targeted risk reduction strategies (e.g., women
with high-risk genotypes could be targeted for interventions
aimed at increasing folic acid supplementation). We have
previously analyzed these data using a sequential (i.e., SNP-
by-SNP) approach to assess associations between CTRD and
both the maternal genotype and the inherited genotype.
Here, we summarize additional analyses that consider poten-
tial maternal and inherited gene-gene interaction eﬀects, as
well as heterogeneity in the eﬀect of the inherited genotype
across the CTRD component phenotypes.
2.MaterialsandMethods
2.1. Study Subjects. Details of this family-based, case-parent
triad study have been provided previously [8]. Brieﬂy,
individuals with a CTRD were ascertained through the
clinical practices of the Children’s Hospital of Philadelphia
between 1997 and 2007. Patients of either sex and of
any race/ethnicity, with a diagnosis of tetralogy of Fallot
(TOF), D-transposition of the great arteries (D-TGA),
double outlet right ventricle (DORV), truncus arteriosus
(TA), interrupted aortic arch (IAA), conoventricular or
posterior malalignment type ventricular septal defect (VSD),
or an isolated aortic arch anomaly (AAA) were eligible
to be cases in this study. Medical records were reviewed
to conﬁrm the cardiac diagnosis for each case. Potential
subjects who had a recognized syndrome, including the
22q11 deletion syndrome, were excluded so as to reduce
etiologic heterogeneity among the cases.
Blood samples were collected from cases prior to a blood
transfusion at the time of surgical or other interventions.
Blood, buccal, or saliva samples were collected from each
participating parent, however, participation of both parents
was not required [12].
2.2. Laboratory Methods. DNA, regardless of sample type,
was extracted using the Puregene DNA isolation kit (Gen-
tra Systems, Minneapolis, MN) according to the manu-
facturer’s protocol. Ten polymorphisms from nine genes
in the folate metabolic pathway, including eight single
nucleotide polymorphisms: BHMT G742A (rs3733890),
MCP1 A251G (rs1024611), MTHFR C677T (rs1801133),
MTHFR A1298C (rs1801131), MTR A2756G (rs1805087),
MTRR A66G (rs18013940), SHMT C1420T (rs1979277),
TCN2 C777G (rs1801198) and two insertion/deletion alleles:
CBS844ins68andDHFRintron119-basepairdeletion,were
genotyped as previously described [8]. Each of these variants
has been shown to inﬂuence the function of the resulting
gene product [13–22]. Genotyping of single nucleotide
polymorphisms was conducted in the High-Throughput
Genotyping Core Laboratory at the Molecular Diagnosis
and Genotyping Facility at the University of Pennsylvania,
using the ABI 7900HT Sequence Detection System (Applied
Biosystems, Foster City, California). The insertion/deletion
polymorphisms were genotyped using published polymerase
chain reaction-based assays [8, 23] and visualized on agarose
gels.
2.3. Statistical Methods. All statistical analyses included a
single case per family (e.g., in a family with two aﬀected
oﬀspring, one child was randomly selected to serve as
the case and the other child was not included in the
study). None of the cases were known to be related. Case
and parental characteristics were summarized using counts
and proportions. For each analyzed genetic variant, the
proportion of samples for which a genotype could not be
assigned, the proportion of samples that yielded discrepant
results on repeated genotypes, and the proportion of triads
thathadgenotypecombinationsthatwereincompatiblewith
Mendelian inheritance were determined. For each sample,
the number of genotyping failures (i.e., genotypes that
could not be assigned or were discrepant across repeated
genotypes) was determined. These analyses were performed
using SAS version 9.1 (SAS Institute Inc).
Multifactor dimensionality reduction-phenomics
(MDR-P) [24] was used to assess the association between
inherited gene-gene interactions and CTRD and to
determine whether the association was inﬂuenced by
heterogeneity across the seven speciﬁc CTRD component
phenotypes included in the case deﬁnition [24]. MDR-P
uses a permutation method to estimate P-values that are
adjusted for multiple testing. All one-, two-, three-, and
four-locus models derived from the ten genotyped folate
metabolicgeneticvariantswereassessed.Theseanalyseswere
implemented with the computer program MDR-Phenomics
[24], using data from triads with complete genotype data for
all variants included in a given model.
Given that MDR-P uses information on the transmission
of alleles from parents to an aﬀected oﬀspring to assess asso-
ciations,thismethodcannotbeusedtoassessmaternalgene-
gene interactions in case-parent triad data. Consequently,
a case-only approach was used to assess maternal gene-
gene interactions [25]. Speciﬁcally, for case mothers, all
pairwise gene-gene combinations were assessed (e.g., BHMT
G742A/MCP1A251G,BHMT G742A/MTHFRC677T).Chi-
square tests were used to obtain unadjusted P-values. All
case-onlyanalyseswererestrictedtodatafromwhitemothers
due to the potential for population stratiﬁcation bias [26].
T h e s ea n a l y s e sw e r ep e r f o r m e du s i n gS A Sv e r s i o n9 . 1( S A S
Institute Inc).
Maternal gene-gene combinations that were associated
with CTRD in the case-only analyses (i.e., unadjusted
P < .05) were investigated using log-linear models for
joint eﬀects in order to obtain eﬀect estimates [27]. To
test the no-interaction null hypothesis, we calculated a 2-
degree-of-freedom likelihood ratio test (LRT) statistic as
twice the diﬀerence of the log likelihoods for the log-linear
model that included two parameters indexing the inherited
genotype for SNP1, two parameters indexing the maternal
genotype for SNP1, and two interaction terms representing
the product of maternal SNP1-SNP2 pairwise genotypes and
a reduced model that excluded the interaction terms. These
analyses were run using LEM [28], a program for log-linearJournal of Biomedicine and Biotechnology 3
Table 1: Characteristics of study cases and parents, Children’s
Hospital of Philadelphia, 1997–2007.
Characteristic Total (%) (n = 727)
Oﬀspring sex
Male 430 (59.2)
Female 297 (40.8)
Race/ethnicity (parental mating pairs)
White 525 (72.2)
Black 74 (10.2)
Hispanic 22 (3.0)
Asian 20 (2.8)
Mixed 86 (11.8)
Primary diagnosis
Tetralogy of Fallot (TOF) 279 (38.4)
D-transposition of the great artery (D-TGA) 152 (20.9)
Ventricular septal defect (VSD)∗ 146 (20.1)
Double outlet right ventricle (DORV) 72 (9.9)
Isolated aortic arch anomaly (AAA) 38 (5.2)
Truncus arteriosus (TA) 21 (2.9)
Interrupted aortic arch (IAA) 19 (2.6)
∗Conoventricular or posterior malalignment type ventricular septal defect;
coarctation of the aorta was present in 16 of the case individuals with a VSD.
analysis with missing data that allows information from
triads that have not been completely genotyped (e.g., father
not available) to be included in the analysis for any given
variant [12]. To reduce concerns regarding possible mating
stratiﬁcation bias [26, 29], only data from triads in which
both parents were reported to be white were used in these
analyses.Giventheexploratorynatureoftheseanalyses,both
unadjustedandadjusted(i.e.,Bonferronicorrected)P-values
are presented.
3. Results
Details of the study sample have been provided elsewhere
[8]. Brieﬂy, there were 727 case-parent triads in which the
case individual had a CTRD (Table 1). The most common
diagnoses among the cases were tetralogy of Fallot (38.4
percent), D-transposition of the great arteries (20.9percent),
and ventricular septal defect (20.1percent). There was a
predominance of males among the cases (59.2percent),
and the majority of parents were reported to be white
(72.2percent).
DNA samples were available for 1991 members of the
study triads (i.e., 537 complete triads and 190 case-parent
pairs). Genotype call rates for these 1991 samples ranged
from 96% to 98% for each variant; the proportion of
samples that provided discrepant results on repeat genotypes
ranged from 0% to 0.8%; and the proportion of triads
with genotype combinations that were incompatible with
Mendelian inheritance ranged from 0.7% to 2.5% (n = 5–
19families) per variant. On the basis of these results, all
of the genotypes were considered to be of suﬃciently high
quality to include in the subsequent statistical analyses.
However, all genotype data from families that included at
least one genotype combination that was incompatible with
Mendelian inheritance were omitted from all analyses (n =
225 samples from 75 triads with a Mendelian inconsistency
for one or more variant). In addition, all genotype data
from individual samples that failed (i.e., no genotype called)
or provided discrepant results on repeat genotyping for
four or more of the genotyped variants were omitted from
all analyses (n = 55samples). After the above-mentioned
exclusions, 652 families (90%) were available for analysis,
and the number of useable genotypes for each of the variants
ranged from 1685 to 1715.
In our previous SNP-by-SNP analyses of these data [8],
three of the ten folate metabolic variants were found to
be associated with CTRD at P (unadjusted) < .05: MTR
A2756G (maternal eﬀect, P = .04), CBS 844ins68 (inherited
eﬀect, P = .05), and MTHFR A1298C (inherited eﬀect, P
= .002). However, only the association with the inherited
MTHFR A1298C genotype remained signiﬁcant when the
false discovery rate was controlled at 0.05 (unadjusted P =
.0021 < .0025).
MDR-Pwasusedtoevaluateinheritedgene-geneinterac-
tions and heterogeneity across the seven CTRD component
phenotypes. Using this approach, the only model achieving
signiﬁcance was the one-locus model for the MTHFR
A1298C variant (adjusted P = .02). There was no evidence
of heterogeneity in the association of this variant across the
seven CTRD component phenotypes, and no other one-,
two-, three-, or four-locus model had an adjusted P value <
.05 (Table 2).
Thecase-onlyapproachwasusedtoassesstheassociation
of CTRD with maternal gene-gene interactions (Table 3).
Using this approach, two maternal gene-gene combinations
were associated with CTRD with unadjusted P values less
than .05: MTHFR C677T/CBS 844ins68 (unadjusted P =
.01) and MTHFR A1298C/CBS 844ins68 (unadjusted P =
.02). Based on the data presented in Table 4, the MTHFR
677 TT genotype is over-represented and the MTHFR 1298
CC genotype is under-represented among case-mothers with
the CBS NN genotype. As these two MTHFR variants are
in strong linkage disequilibrium [8, 30, 31], and given
prior evidence that homocysteine levels are inﬂuenced by
a MTHFR C677T/CBS 844ins68 interaction [32], only the
MTHFR C677T/CBS interaction was evaluated using log-
linear analyses.
In the log-linear analyses, the maternal CBS 844ins68 IN
and II genotypes were combined, due to the small number
of II genotypes (n = 4), and the two resulting categories (NN
versus IN + II) were used to stratify the data. An unrestricted
model, which provides eﬀect estimates for heterozygotes and
for rare homozygotes, was ﬁtted to the maternal MTHFR
C677T genotype data. For these analyses, data from mothers
who were genotyped for the MTHFR C677T but not the CBS
844ins68 variant were excluded (n = 2). Mothers who were
CBS NN and MTHFR 677 TT had a 1.85-fold (95 percent
conﬁdence interval: 1.13, 3.02) higher risk of having a child
with a CTRD as compared to those who were CBS NN and
MTHFR 677 CC. This association was not seen in mothers
with the CBS IN or II genotypes (Table 5). The unadjusted4 Journal of Biomedicine and Biotechnology
Table 2: MDR-P results (adjusted P values) for all 2-locus models of the inherited genotype and CTRD, Children’s Hospital of Philadelphia,
1997–2007.
BHMT CBS DHFR MCP1 MTHFR MTHFR MTR MTRR SHMT TCN2
G742A 844ins68 19-bp del A251G C677T A1298C A2756G A66G C1420T C777G
BHMT G742A 0.75 0.27 0.69 0.43 0.18 0.50 0.68 0.92 0.57
CBS 844ins68 0.40 0.38 0.59 0.09 0.48 0.92 0.45 0.63
DHFR 19-bp del 0.92 0.60 0.72 0.82 0.28 0.26 0.86
MCP1 A251G 0.58 0.83 0.60 0.53 0.47 0.67
MTHFR C677T N/A∗ 0.30 0.60 0.43 0.10
MTHFR A1298C 0.13 0.23 0.13 0.32
MTR A2756G 0.57 0.13 0.74
MTRR A66G 0.88 0.18
SHMT C1420T 0.93
∗This interaction was not assessed as the two MTHFR variants are in strong linkage disequilibrium.
Table 3: Case-only results (unadjusted P values) for all pairwise combinations of maternal genotypes and CTRD, Children’s Hospital of
Philadelphia, 1997–2007.
BHMT CBS DHFR MCP1 MTHFR MTHFR MTR MTRR SHMT TCN2
G742A 844ins68 19-bp del A251G C677T A1298C A2756G A66G C1420T C777G
BHMT G742A 0.95 0.64 0.71 0.15 0.56 0.92 0.06 0.38 0.92
CBS 844ins68 0.28 0.98 0.01 0.02 0.94 0.65 0.27 0.36
DHFR 19-bp del 0.95 0.41 0.59 0.14 0.81 0.14 0.17
MCP1 A251G 0.71 0.65 0.64 0.75 0.83 0.19
MTHFR C677T N/A∗ 0.97 0.41 0.57 0.58
MTHFR A1298C 0.57 0.14 0.48 0.74
MTR A2756G 0.42 0.57 0.92
MTRR A66G 0.92 0.28
SHMT C1420T 0.43
∗This interaction was not assessed as the two MTHFR variants are in strong linkage disequilibrium.
Table 4: Maternal MTHFR and CBS 844ins68 genotype combina-
tions, Children’s Hospital of Philadelphia, 1997–2007.
CBS 844ins68
II IN NN P value
MTHFR genotypes
C677T
CC (%) 4 (2.5) 19 (11.8) 138 (85.7)
CT (%) 0 31 (16.0) 163 (84.0)
TT (%) 0 2 (3.6) 54 (96.4) .01
A1298C
AA (%) 1 (0.5) 20 (10.2) 175 (89.3)
AC (%) 1 (0.5) 27 (14.9) 153 (84.5)
CC (%) 2 (6.1) 5 (15.2) 26 (78.9) .02
P-value for the LRT of heterogeneity of the eﬀect of the
maternal MTHFR C677T genotype across categories deﬁned
by the maternal CBS 844ins68 insertion genotype was 0.02,
but this association was not signiﬁcant at the 0.05 level, after
applying the Bonferroni correction for the evaluation of all
44 maternal gene-gene combinations (P = .02 > .001).
Table 5: Relative risk of CTRD for maternal MTHFR C677T/CBS
844ins68genotypecombinationsestimatedbylog-linearregression,
Children’s Hospital of Philadelphia, 1997–2007.
CBS 844ins68
II/IN NN
RR (95% CI) RR (95% CI) P for
interaction∗
MTHFR
C677T
CC 11
CT 1.26 (0.59,2.69) 1.10 (0.79,1.53)
TT 0.57 (0.10,3.45) 1.85 (1.13,3.02) .02
∗Based on the likelihood ratio test of no interaction.
4. Discussion
We have previously reported that the inherited MTHFR
A1298C genotype is associated with the risk of CTRD,
and others have observed a similar association in CHD
samples including, but not limited to CTRD [8, 9]. Our
results using MDR-P are consistent with these previous
ﬁndings and provide evidence that this association is similarJournal of Biomedicine and Biotechnology 5
across the seven component CTRD phenotypes (TOF, D-
TGA, VSD, DORV, AAA, TA, and IAA). However, based
on these analyses, there is no evidence that the inherited
MTHFR A1298C genotype inﬂuences the risk of CTRD via
interactions with the other measured genotypes, or that
other measured folate metabolic genotype combinations
inﬂuence CTRD risk.
The SNP-by-SNP analyses of these data provided little
evidence that the risk of CTRD is inﬂuenced by maternal
genotype for any of the measured variants [8]. How-
ever, analyses of pairwise maternal gene-gene combinations
suggested that a maternal MTHFR C677T/CBS 844ins68
interaction is associated with the risk of CTRD in oﬀspring.
Speciﬁcally, based on our analyses of these data, women with
the MTHFR TT genotype appear to be at increased risk of
having a child with CTRD, relative to women with CC geno-
type, only if they also carry the CBS NN genotype. Although
this association did not achieve statistical signiﬁcance after
correction for multiple testing, it is in line with studies
showing that the high homocysteine, low folate phenotype
commonly observed in individuals with the MTHFR 677
TT genotype is present only among individuals with the
CBS 844ins68 NN genotype [32–34]. Further, there is some
evidence that interactions between these two variants may
inﬂuence the risk of neural tube defects [35–38].
This study had several strengths, including a largesample
size and consideration of the joint eﬀects of genetic variants
within the folate metabolic pathway. In addition, the eﬀects
of both the maternal and inherited genotypes were con-
sidered, as was heterogeneity of the eﬀects of the inherited
genotype across the component CTRD phenotypes. It is
of note that in this large sample, the association between
CTRD risk and the inherited MTHFR A1289C genotype did
not appear to diﬀer across the various CTRD phenotypes,
which provides support for the inclusion of the full range of
CTRDphenotypesinstudiesaimedatidentifying CTRDrisk
factors.
As with all studies, this study also had limitations.
Although this is the largest and most comprehensive study of
CTRD and genes in the folate metabolic pathway conducted
to date, it included only ten variants in nine folate metabolic
genes. Further, heterogeneity within the case group may have
inﬂuenced the observed associations, although results from
MDR-P provide some evidence that the component CTRD
phenotypes can be combined for analysis. In addition, the
power to detect weak to moderate gene-gene interaction
eﬀects was low, and this limitation was further compounded
by the relatively large number of interactions that were
evaluated.Hence,althoughtheobservedassociationbetween
CTRD and the maternal MTHFR C677T/CBS 844ins68
interaction is consistent with the biochemical consequences
of this gene-gene combination, it is based on small numbers
and may represent a false-positive ﬁnding.
5. Conclusions
The results of our study are consistent with the previous
studies in this and other populations that indicate an associ-
ation between the inherited MTHFR A1298C genotype and
CHDs. In addition, our results suggest that this association
is similar for each of the CTRD component phenotypes
and, therefore, provides some support for pooling data
from the component phenotypes in analyses aimed at
identifying CTRD risk factors. The results of these analyses
also indicate that a maternal MTHFR C677T/CBS 844ins68
interaction may be associated with the risk of CTRD in
oﬀspring. However, this ﬁnding requires conﬁrmation in
independent study samples. Hence, larger studies, which
include additional folate metabolic pathway genes and a
moreextensivesetofSNPs,areneededtomorefullyelucidate
the role of folate in CTRD.
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